概览

Conference: September 23-25, 2026

The DIA Oligonucleotide-Based Therapeutics Conference brings together leading experts to inform, educate, and share advancements in oligonucleotide-based therapeutic product development. Developed collaboratively by regulators, industry professionals, and academics, the program covers a wide range of topics from the nonclinical, CMC, and clinical areas, including emerging CMC guidances and considerations, learnings from recent regulatory filings, extra-hepatic and CNS delivery of oligonucleotides, toxicology testing, gene editing, and safety assessments. The conference offers a unique three-day experience with multiple perspectives presented, and the opportunity to interface with regulators from around the globe.

While we develop our 2026 agenda, please take a moment to review the 2024 Final Agenda!

Participant Testimonials

The DIA/FDA Oligonucleotide Conference is an interactive and dynamic meeting that provides key data and strategic updates. This meeting allows for sharing of information, learning and excellent networking. The collaboration between industry and health authority sponsors at this meeting provides an excellent well rounded perspective for Oligo drug development spanning from nonclinical to clinical and inclusive of CMC and Reg perspectives. – Eileen Blasi, Avidity Biosciences

A highlight among the year’s oligonucleotide meetings. Strongly recommend attending to hear and discuss the state of the art with the leaders in the field from across industry and regulators. – Dan Swerdlow, GSK

Planning for DIA’s Oligonucleotide-Based Therapeutics Conference is underway.

To ensure that we have the most comprehensive and cutting-edge program, we need your input!

We are excited to launch TWO ways to contribute to the 2026 program agenda! We have both a Call for Topics and Call for Abstracts.

Call For Topics:

By sharing your thoughts, you’ll help us better understand the evolving needs of the community and guide the direction of this year’s conference content.

Please note: Submitting a topic suggestion does not imply a speaking or chairing role at the conference.

Deadline: December 3

Provide Feedback Here

Call for Abstracts:

We are seeking abstract submissions from professionals like yourself, who are pushing the boundaries in their respective fields. We encourage you to submit abstracts that reflect the latest trends, innovations, and best practices in oligonucleotide-based therapeutics. We will be accepting the following formats:

Presentations: 15-20-minute presentation to be bundled with other presentations to create a session (1 author/speaker)

Sessions: 60-75-minute total session (1 author/speaker + 2 additional speakers)

Workshop: 60-75-minute workshop delivered in an interactive/simulation or role-playing format (1 author/speaker + 2 additional speakers)

Deadline: January 14, 2026

VIEW GUIDELINES

SUBMIT

Featured

Want to learn more about Oligonucleotide-Based Therapeutics Conference? You've come to the right site!

Highlights & Features

了解更多

Highlights & Features

了解更多

学习目标

Learning Objectives:

At the conclusion of this activity, participants should be able to:
- Analyze the latest strategies for clinical use of oligonucleotide therapies and explain the specific challenges of developing RNA-based therapeutics
- Describe the chemistry, manufacturing, and controls challenges associated with the development of oligonucleotides, including formulation and specification issues
- Describe the technology landscape, CMC challenges, and regulatory considerations associated with novel oligonucleotide delivery approaches
- Explain the latest global regulatory updates in oligonucleotide therapeutic developments

项目委员会

Barry Ticho, MD, PHD Chief Medical Officer
Stoke Therapeutics, United States
Benjamin Stevens, PHD, MPH Director CMC Policy and Advocacy
GlaxoSmithKline, United States
Jeffrey Foy, PHD Senior VP, Toxicology
PepGen Inc., United States
Hobart Rogers, PHARMD, PHD Pharmacologist, CDER
FDA, United States
Andrew Slugg, MBA, MS Senior Vice President, Global Head of Regulatory Sciences
Alnylam Pharmaceuticals, United States
Sydney Stern, PHD, MS Pharmacokineticist, CDER
FDA, United States
Patrik Andersson, PHD Senior Director, RNA Therapeutics Safety
AstraZeneca R&D, Sweden
Elena Braithwaite, PHD Toxicologist
FDA, United States
Xuan Chi, PHD Supervisory Pharmacologist
CDER, FDA, United States
Tae-Won Kim Executive Director, Toxicology
Ionis Pharmaceuticals, Inc., United States
Aimee Jackson, PHD CSO
Atalanta Therapeutics, United States
Ramin Darvari, PHD, MS Research Fellow
Pfizer Inc., United States
René Thürmer, PHD Quality Assessor
Federal Institute for Drugs and Medical Devices, Germany
Dominik Altevogt, PHD Director Regulatory Affairs CMC
Novartis, Switzerland
Rumi Raquel Young, MS Director, Regulatory Policy
Novo Nordisk A/S, United States
Katherine Windsor, PHD Senior Pharmaceutical Quality Assessor, CDER
Food and Drug Administration, United States
Louis St. L. O'Dea, MD Independent Consultant
United States
Dan Swerdlow, MD, PHD Senior Director, Early Clinical Development
GSK, United Kingdom
Scott Henry, PHD Senior Vice President, Nonclinical Development
Ionis Pharmaceuticals, Inc., United States
Arthur A. Levin, PHD Distinguished Scientist
Avidity Biosciences, United States
James Wild, PHD, MS Pharmacologist, CDER
FDA, United States